GLP-1 and Insulin Resistance: Clinical Evidence and Biomarkers

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 receptor agonists may help improve insulin sensitivity in patients with insulin resistance, though the degree of benefit varies significantly between individuals. Clinical studies show that GLP-1 medications improve fasting insulin levels and HOMA-IR scores, key markers of insulin function, independent of weight loss alone.

Understanding your baseline metabolic status—including insulin levels, glucose metabolism, and genetic predispositions in peptide pathways—can support a more informed conversation with your provider about whether GLP-1 therapy is appropriate for your specific situation. This precision-wellness approach moves beyond one-size-fits-all treatment assumptions.

How GLP-1 Medications Address Insulin Resistance at the Cellular Level

GLP-1 receptor agonists work through multiple mechanisms to improve insulin sensitivity. These medications enhance pancreatic beta cell function, slow gastric emptying to reduce postprandial glucose spikes, and promote weight loss, all of which reduce the metabolic demand on insulin-producing cells and improve tissue insulin sensitivity.

Research indicates that GLP-1 medications improve insulin resistance markers within weeks of initiation, often before significant weight loss occurs. This suggests direct metabolic benefits beyond simple caloric reduction, making GLP-1 therapy potentially valuable for patients with metabolic dysfunction even at lower weights.

Key Biomarkers and Clinical Evidence Supporting GLP-1 Efficacy in Insulin Resistance

Several biomarkers predict GLP-1 response in insulin resistance. Baseline HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), fasting insulin levels, C-peptide, and HbA1c provide context for evaluating treatment effectiveness. Genetic variants in GLP1R and GIPR pathways may also influence individual metabolic response patterns.

Biomarker	What It Measures	Why It Matters for GLP-1 Response	Typical Normal Range
HOMA-IR	Insulin resistance index calculated from fasting glucose and insulin	Higher baseline HOMA-IR may indicate greater room for GLP-1-driven improvement	< 2.0 suggests normal insulin sensitivity
Fasting Insulin	Circulating insulin at rest; indicates pancreatic demand	Elevated fasting insulin suggests insulin resistance; GLP-1 may reduce compensatory secretion	< 12 mIU/mL typically considered normal
HbA1c	3-month average blood glucose; gold standard for glycemic control	GLP-1 reduces HbA1c 0.5–1.5% in insulin-resistant patients depending on baseline severity	< 5.7% non-diabetic; 5.7–6.4% prediabetic
C-Peptide	Indicator of endogenous insulin production; reflects beta cell function	GLP-1 enhances beta cell preservation and function; improved C-peptide suggests better pancreatic health	Fasting 0.8–3.1 ng/mL; higher can indicate greater compensatory demand

Genetic Predispositions That May Influence GLP-1 Effectiveness in Insulin Resistance

Specific genetic variants in GLP1R and GIPR genes influence how efficiently your cells respond to GLP-1 signaling. The Precision Peptide Genetic Test screens for key variants such as GLP1R rs6923761 and GIPR rs1800437, which may provide context about your genetic predisposition in peptide hormone pathways relevant to insulin metabolism.

Understanding these genetic markers should not be interpreted as predicting exact medication response. Instead, genetic insights may help your provider understand baseline metabolic tendencies and support a more personalized conversation about treatment timing, dosing, and combination approaches. This context strengthens shared decision-making between you and your healthcare team.

Patient Selection and Safety Considerations: Who Benefits Most from GLP-1 for Insulin Resistance

GLP-1 therapy may be most appropriate for patients with documented insulin resistance (HOMA-IR > 2.0), prediabetes or type 2 diabetes, metabolic dysfunction, or weight-related metabolic concerns. Conversely, patients with type 1 diabetes, acute pancreatitis history, or certain thyroid conditions require careful provider evaluation before starting. Pregnancy is a contraindication for most GLP-1 medications.

Before initiating GLP-1 therapy, comprehensive metabolic assessment including fasting glucose, insulin levels, kidney function, and family history of medullary thyroid cancer should be completed. Work closely with your provider to establish baseline biomarkers, confirm appropriate patient selection, and monitor response over 8–12 weeks. Dosing adjustments based on individual tolerance and efficacy are standard practice.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your genetic predisposition in key peptide pathways (GLP1R, GIPR, FTO, MC4R variants) relevant to insulin metabolism and metabolic response. This genetic context, combined with your clinical biomarkers, should be interpreted with a qualified healthcare provider to inform personalized GLP-1 treatment decisions.

The genetic test reveals predispositions in peptide genetic pathways—not pharmacogenomic drug metabolism. Variants such as GLP1R rs6923761 and GIPR rs1800437 provide insight into baseline receptor function and metabolic tendency, helping you understand whether GLP-1 signaling optimization may align with your genetic profile. This is one data point among many in a comprehensive metabolic picture.

When combined with clinical biomarkers (HOMA-IR, fasting insulin, HbA1c, C-peptide) and your medical history, genetic predisposition data can support a richer conversation with your provider about treatment rationale, expected timelines, and whether compounded GLP-1 options (semaglutide, tirzepatide, or microdose GLP-1 protocols) suit your metabolic needs and goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.